Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair
Gastric Cancer · 2024-09 · 27 (5) · 907-931
DOI: 10.1007/s10120-024-01523-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Gastric Cancer, online erschienen am 26.06.2024. Verfasst von Akira Ooki und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-Ku, Tok…. Hauptthemen laut MEDLINE: Microsatellite Instability, Stomach Neoplasms, DNA Mismatch Repair. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 281 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Gastric cancer (GC) is a common malignancy that presents challenges in patient care worldwide. The mismatch repair (MMR) system is a highly conserved DNA repair mechanism that protects genome integrity during replication. Deficient MMR (dMMR) results in an increased accumulation of genetic errors in microsatellite sequences, leading to the development of a microsatellite instability-high (MSI-H) phenotype. Most MSI-H/dMMR GCs arise sporadically, mainly due to MutL homolog 1 ( MLH1 ) epigenetic silencing. Unlike microsatellite-stable (MSS)/proficient MMR (pMMR) GCs, MSI-H/dMMR GCs are relatively rare and represent a distinct subtype with genomic instability, a high somatic mutational burden, favorable immunogenicity, different responses to treatment, and prognosis. dMMR/MSI-H status is a robust predictive biomarker for treatment with immune checkpoint inhibitors (ICIs) due to high neoantigen load, prominent tumor-infiltrating lymphocytes, and programmed cell death ligand 1 (PD-L1) overexpression. However, a subset of MSI-H/dMMR GC patients does not benefit from immunotherapy, highlighting the need for further research into predictive biomarkers and resistance mechanisms. This review provides a comprehensive overview of the clinical, molecular, immunogenic, and therapeutic aspects of MSI-H/dMMR GC, with a focus on the impact of ICIs in immunotherapy and their potential as neoadjuvant therapies. Understanding the complexity and diversity of the molecular and immunological profiles of MSI-H/dMMR GC will drive the development of more effective therapeutic strategies and molecular targets for future precision medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-Ku, Tokyo, 135-8550, Japan. sp9y9tq9@piano.ocn.ne.jp.
- Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-Ku, Tokyo, 135-8550, Japan.
ORCID-Profile: Akira Ooki
Zitieren
APA
Ooki, A., Osumi, H., Yoshino, K., & Yamaguchi, K. (2024). Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair. Gastric Cancer, 27(5), 907-931. https://doi.org/10.1007/s10120-024-01523-4
Vancouver
Ooki A, Osumi H, Yoshino K, Yamaguchi K. Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair. Gastric Cancer. 2024;27(5):907-931. doi:10.1007/s10120-024-01523-4
BibTeX
@article{Ooki2024,
author = {Ooki, Akira and Osumi, Hiroki and Yoshino, Koichiro and Yamaguchi, Kensei},
title = {Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair},
journal = {Gastric Cancer},
year = {2024},
volume = {27},
number = {5},
pages = {907--931},
doi = {10.1007/s10120-024-01523-4}
}
EUVIMED